Resultats de la cerca - Daneng Li

  • Mostrar 1 - 18 resultats de 18
Refinar resultats
  1. 1
    Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life

    Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life per Daneng Li, Sabrina Sedano, Rebecca S. Allen, Jun Gong, May Cho, Sunil Sharma

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  2. 2
    IMbrave152/SKYSCRAPER-14: a Phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma

    IMbrave152/SKYSCRAPER-14: a Phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma per Shreya Badhrinarayanan, Christopher Cotter, Huaqi Zhu, Ya‐Chen Lin, Masatoshi Kudo, Daneng Li

    Publicat 2024
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial

    Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial per Riad Salem, Daneng Li, Nicolas Sommer, Sairy Hernandez, Wendy Verret, Beiying Ding, Riccardo Lencioni

    Publicat 2021
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial

    Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial per Daneng Li, Han Chong Toh, Philippe Merle, Kaoru Tsuchiya, Sairy Hernandez, Wendy Verret, Alan Nicholas, Masatoshi Kudo

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Barriers to Participation in Therapeutic Clinical Trials as Perceived by Community Oncologists

    Barriers to Participation in Therapeutic Clinical Trials as Perceived by Community Oncologists per Andrew R. Wong, Virginia Sun, Kevin George, Jennifer Liu, Simran Padam, Brandon Chen, Thomas George, Arya Amini, Daneng Li, Mina S. Sedrak

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Adjuvant Chemoradiation in Resected Biliary Adenocarcinoma: Evaluation of SWOG S0809 with a Large National Database

    Adjuvant Chemoradiation in Resected Biliary Adenocarcinoma: Evaluation of SWOG S0809 with a Large National Database per Dana A. Dominguez, Paul Wong, Yi‐Jen Chen, Gagandeep Singh, Yuman Fong, Daneng Li, Philip H. G. Ituarte, Laleh G. Melstrom

    Publicat 2024
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150

    Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150 per Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann‐Lii Cheng, Norelle R. Reilly, Alan Nicholas, Sairy Hernandez, Ning Ma, Philippe Merle, Riad Salem, Daneng Li, В. В. Бредер

    Publicat 2024
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer

    A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer per Richard D. Kim, Vincent Chung, Olatunji B. Alese, Bassell F. El-Rayes, Daneng Li, Taymeyah Al‐Toubah, Michael J. Schell, Jun-Min Zhou, Amit Mahipal, Baek‐hui Kim, Dae Won Kim

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Distress in Older Patients With Cancer

    Distress in Older Patients With Cancer per Arti Hurria, Daneng Li, Kurt Hansen, Sujata Patil, Ravi Gupta, Christian J. Nelson, Stuart M. Lichtman, William P. Tew, Paul A. Hamlin, Enid Zuckerman, Jonathan Gardes, Sewanti Limaye, Mark S. Lachs, Eva Kelly

    Publicat 2009
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study

    Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised,... per Richard Finn, Baek‐Yeol Ryoo, Chiun Hsu, Daneng Li, Adam M. Burgoyne, Christopher Cotter, Shreya Badhrinarayanan, Yulei Wang, Anqi Yin, Tirupathi Rao Edubilli, Sami Mahrus, Matthew H. Secrest, Colby S. Shemesh, Nancy Xiaonan Yu, Stephen P. Hack, Edward Cha, Edward Gane

    Publicat 2025
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms

    Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms per James C. Yao, Jonathan Strosberg, Nicola Fazio, Marianne Pavel, Emily K. Bergsland, Philippe Ruszniewski, Daniel M. Halperin, Daneng Li, Salvatore Tafuto, Nitya Raj, Davide Campana, Susumu Hijioka, Markus Raderer, Rosine Guimbaud, Pablo Gajate, Sara Pusceddu, Albert Reising, Evgeny Degtyarev, Mark Shilkrut, Simantini Eddy, Simron Singh

    Publicat 2021
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

    Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma per Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux, Tae‐You Kim, Ho Yeong Lim, Masatoshi Kudo, В. В. Бредер, Philippe Merle, Ahmed O. Kaseb, Daneng Li, Wendy Verret, Ning Ma, Alan Nicholas, Yifan Wang, Lindong Li, Andrew X. Zhu, Richard S. Finn

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Outcome prioritization and preferences among older adults with cancer starting chemotherapy in a randomized clinical trial

    Outcome prioritization and preferences among older adults with cancer starting chemotherapy in a randomized clinical trial per Enrique Soto‐Pérez‐de‐Celis, William Dale, Vani Katheria, Heeyoung Kim, Marwan Fakih, Vincent Chung, Dean Lim, Joanne Mortimer, Leana Cabrera Chien, Kemeberly Charles, Elsa Roberts, Jessica Vázquez, Jeanine Moreno, Tak Yan Lee, Simone Fernandes Dos Santos Hughes, Mina S. Sedrak, Can‐Lan Sun, Daneng Li

    Publicat 2024
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Geriatric Assessment–Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer

    Geriatric Assessment–Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer per Daneng Li, Can‐Lan Sun, Heeyoung Kim, Enrique Soto‐Pérez‐de‐Celis, Vincent Chung, Marianna Koczywas, Marwan Fakih, Joseph Chao, Leana Cabrera Chien, Kemeberly Charles, Simone Fernandes Dos Santos Hughes, Vani Katheria, Monica Trent, Elsa Roberts, Reena Jayani, Jeanine Moreno, Cynthia M. Kelly, Mina S. Sedrak, William Dale

    Publicat 2021
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

    Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma per Richard S. Finn, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux, Tae‐You Kim, Masatoshi Kudo, В. В. Бредер, Philippe Merle, Ahmed O. Kaseb, Daneng Li, Wendy Verret, Derek-Zhen Xu, Sairy Hernandez, Juan Liu, Chen Huang, Sohail Mulla, Yulei Wang, Ho Yeong Lim, Andrew X. Zhu, Ann‐Lii Cheng

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer

    Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer per Bihong T. Chen, Taihao Jin, Sunita K. Patel, Ningrong Ye, Can-Lan Sun, Huiyan Ma, Russell C. Rockne, James C. Root, Andrew J. Saykin, Tim A. Ahles, Andrei I. Holodny, Neal Prakash, Joanne Mortimer, James Waisman, Yuan Yuan, Daneng Li, George Somlo, Jessica Vázquez, Abrahm Levi, Heidi Tan, Richard Yang, Vani Katheria, Arti Hurria

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers

    Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers per Mark Yarchoan, Leslie Cope, Amanda N. Ruggieri, Robert A. Anders, Anne M. Noonan, Laura W. Goff, Lipika Goyal, Jill Lacy, Daneng Li, Anuj Patel, Aiwu Ruth He, Ghassan K. Abou‐Alfa, Kristen Spencer, Edward Kim, S. Lindsey Davis, Autumn J. McRee, Paul R. Kunk, Subir Goyal, Yuan Liu, Lauren Dennison, Stephanie Xavier, Aditya Mohan, Qingfeng Zhu, Andrea Wang‐Gillam, Andrew Poklepovic, Helen X. Chen, Elad Sharon, Gregory B. Lesinski, Nilofer S. Azad

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

    Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study per James J. Harding, Jia Fan, Do‐Youn Oh, Hye Jin Choi, Jin Won Kim, Heung-Moon Chang, Lequn Bao, Hui‐Chuan Sun, Teresa Macarulla, Feng Xie, Jean‐Philippe Metges, Jieer Ying, John Bridgewater, Myung Ah Lee, Mohamedtaki Abdulaziz Tejani, Emerson Y. Chen, Dong Uk Kim, Harpreet Wasan, Michel Ducreux, Yuanyuan Bao, Lisa Boyken, Jiafang Ma, Phillip M. Garfin, Shubham Pant, Ghassan K. Abou‐Alfa, J. Adeva Alfonso, Massimo Aglietta, Ari David Baron, Muhammad Shaalan Beg, Paula Carrasco Aguirre, Eric X. Chen, Ying Cheng, Antonio Cubillo Gracián, Laëtitia Dahan, Filippo de Braud, Elisabetta Fenocchio, Olumide Gbolohon, Roopinder Gillmore, Marine Jary, Milind Javle, Yixing Jiang, Jung Hun Kang, Gentry George King, Madappa N. Kundranda, Laura Layos, Daneng Li, Tingbo Liang, Sara Lonardi, Omkar Marathe, Sebastián Mondaca, Andrés J. Muñoz Martín, Joon Oh Park, Roberto Pazo-Cid, Paula Ribera Fernandez, Lorenza Rimassa, Rosa Alonso, Saeed Sadeghi, Aaron J. Scott, Benjamin Tan, David Tougeron, Qiang Yan, Xiaoyu Yin, Haitao Zhao

    Publicat 2023
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: